Knight Therapeutics (GUD.TO) has submitted a supplemental application to the Brazilian health regulatory agency for approval of an additional indication for MINJUVI as a first-line treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma, the company said Thursday.
Tafasitamab is commercialized as MONJUVI in the U.S. and MINJUVI outside the US. MINJUVI has been launched in Brazil, Mexico and Argentina.
McEwen Mining (MUX.TO. MUX) after trade Thursday said its McEwen Copper unit secured a $240-million senior secured loan with a four-year term from a group of lenders.The funding includes $112 million from Sprott Natural Resource Investment Partners, $85 million from Rob McEwen, and $43 million from other lenders, according to the statement.The company said the proceeds will fund engineering and early work on the Los Azules copper project in San Juan, Argentina, as well as general corporate needs.A final investment decision and full project financing are expected in mid-2027, with commercial copper production targeted for 2030, subject to financing and approvals, the company said, adding that McEwen Copper is also preparing for a potential initial public offering.The term loan carries 12% annual interest, paid monthly, with the principal due at maturity. Lenders also received 15,000 five-year warrants for every $1 million borrowed, with an exercise price of $40 per share, the company said.
Inventronics (IVX.V) said Thursday after trade that second-quarter net earnings were relatively flat, edging down slightly to C$0.027 per share, from C$0.028 per share, in the prior year period.The company said revenue rose slightly, to C$2.3 million from C$2.2 million, over the same period.Inventronics shares last traded on Aug. 19, closing unchanged at C$0.75 per share.
Replenish Nutrients Holding (ERTH.CN) after the close on Thursday reported a loss of C$0.01 per share, matching the prior-year period.Revenue for the quarter ended on June 30 fell to C$978,300 from C$1.47 million in the same period last year.